LGALS3 and neurodegenerative disease: Many different clinical trials targeting Gal-3 molecule are still ongoing to treat severe neoplastic, fibrotic, metabolic and degenerative disease and many pharmaceutical companies are investing money and efforts to develop and test drugs targeting the Gal-3 molecule and acting as antagonist or agonist.